Millions of Americans order their prescriptions from Canadian pharmacies. They pay far less than what domestic suppliers charge. That option stands on the verge of vanishing.

On Oct. 22, a new U.S. Customs and Border Protection policy ends the de minimis exemption for international mail shipments of medications. Packages once cleared with minimal scrutiny will now demand detailed documentation, bonds and potential tariffs. The change hits personal imports from Canada, the U.K., Australia and elsewhere. Critics call it a blunt instrument aimed at fentanyl that instead punishes patients seeking relief from high U.S. prices.

The rule grew out of President Donald Trump’s broader campaign against illicit drugs crossing the northern border. He first suspended the de minimis loophole last year, initially targeting China. Officials soon expanded it. The White House frames the move as essential to collect revenue, block dangerous substances and protect American industry. Yet its timing clashes with Trump’s repeated vows to slash prescription costs.

The policy collides with Trump’s signature drug-pricing initiatives.

His administration has signed most-favored-nation agreements with nearly 90% of the branded drug market. A White House spokeswoman, Allison Schuster, told USA Today the deals will save Americans $600 billion over the next decade. Patients have already pocketed more than $1 billion in out-of-pocket reductions, she said. The president also launched TrumpRx, a site promoting discounted medicines.

Those steps don’t reach the millions who turned to Canada out of necessity. A three-month supply of the blood thinner Eliquis costs about $566 from a licensed Canadian pharmacy. The same quantity runs $1,017 on Amazon or $1,029 through GoodRx, according to an August survey by the Campaign for Personal Prescription Importation cited by multiple outlets including The Globe and Mail.

Savings often exceed 60%. Some patients report reductions of 80% or more on maintenance drugs for diabetes, cholesterol and asthma. For retirees on fixed incomes or the underinsured, those margins make the difference between adherence and skipped doses. One patient told reporters the Canadian supply of her asthma medication had become “a matter of life and death.”

Canadian International Pharmacy Association general manager Tim Smith warned that most personal prescription orders mailed from licensed pharmacies will no longer reach U.S. customers. The nonprofit group called the situation “unworkable” without new arrangements. Pharmacy operators in Canada already report early price creep from earlier tariff moves.

But the administration shows little sign of retreat. Trump has tied Canada to the fentanyl crisis for months. Executive orders cited insufficient cooperation from Ottawa on precursor chemicals and trafficking networks. Seizures at the northern border have risen sharply. Mexican cartels operate labs inside Canada, U.S. officials say. Fentanyl potency means even small shipments can kill thousands.

Democrats and some Republicans question the collateral damage. With midterm elections looming and cost of living a top voter concern, the optics look poor. Blocking affordable medicine while touting price cuts invites accusations of contradiction. Public posts on X reflect the frustration. Users shared stories of lost access to preferred medications. One called it “the cost of Trump’s corruption.”

Recent reporting adds context. Reuters noted on Oct. 7 that the pharmaceutical lobby sued the administration over Medicare drug price benchmarking, arguing overreach. The industry fights international price referencing even as patients exploit it through personal imports.

Canada itself faces pressure. Trump’s most-favored-nation approach could prompt drugmakers to raise prices north of the border to protect U.S. revenue, experts told CBC News in September. Manufacturers might delay launches or cut discounts. Canadian officials watch closely.

Trump has also threatened steep tariffs on generic drugs not produced in the United States. A July post outlined 100% tariffs rising to 200% unless companies build American plants. Canada produces mostly generics for export. The policy aims to reshore production. It complicates Ottawa’s efforts to strengthen domestic pharmaceutical capacity.

Trade tensions run deeper. The two countries exchanged 50% tariffs on billions in goods last year over dairy, autos and other disputes. Trump recently claimed Canada imposed “secret” tariffs. U.S. Trade Representative Jamieson Greer said on Oct. 8 that Washington is “holding fast” in talks while Canada deals with a provincial election. Reuters reported the comments.

Patients and advocates see a simpler story. They bought from Canada because U.S. prices remain the highest among developed nations. Federal law technically bars most personal importation, yet enforcement stayed light for years. The de minimis exemption let small packages slip through. Now that door slams shut.

Some hope for carve-outs or new verification systems. Others predict a surge in domestic mail-order programs or pressure on Congress for broader importation legislation. History suggests change comes slowly. Pharmaceutical manufacturers guard their pricing models fiercely.

For now the calendar is fixed. Oct. 22 arrives in two weeks. Millions face higher bills or the search for new suppliers. Shortages could follow for certain drugs. Physicians already field calls from worried patients.

The irony lingers. A president who campaigned on bringing drug prices down may deliver the opposite for a sizable group of voters. His most-favored-nation deals promise future savings. The customs rule delivers immediate pain. How the two forces balance will shape health-care debates through the midterms and beyond.

And the border remains porous in other ways. Fentanyl still flows. Cartels adapt. Canada insists its role is overstated. Data from the RCMP shows most Canadian fentanyl stays domestic. The dispute continues.

One thing looks certain. Americans who relied on that quiet pipeline to cheaper medicine must find another path. Some will pay more. Others may go without. The rule was sold as a security measure. Its human cost lands squarely on patients already struggling with American health-care economics.